Search
Home
Latest
News
North America
Europe
Asia
Middle East
Global
Fortune 500
Fortune 500 U.S.
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Finance
Economy
Banking
Personal Finance
Investing
Real Estate
Energy
Crypto
Tech
Big Tech
Startups & Venture
AI
Innovation
Cybersecurity
Leadership
Future Of Work
Success
C-Suite
Workplace Culture
CEO Initiative
Lifestyle
Arts & Entertainment
Health
Travel & Leisure
Education
Rankings
Great Place To Work
Analytics
Multimedia
Live Media
Magazine
Newsletters
Press Releases
Video
Podcasts
Home
Latest
Latest
News
North America
Europe
Asia
Middle East
Global
Fortune 500
Fortune 500
Fortune 500 U.S.
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Finance
Finance
Economy
Banking
Personal Finance
Investing
Real Estate
Energy
Crypto
Tech
Tech
Big Tech
Startups & Venture
AI
Innovation
Cybersecurity
Leadership
Leadership
Future Of Work
Success
C-Suite
Workplace Culture
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Health
Travel & Leisure
Education
Rankings
Rankings
Great Place To Work
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Press Releases
Video
Podcasts
home
home
GLP-1s
GLP-1s
Success
Ozempic mania has even Olive Garden and The Cheesecake Factory cutting back on portion sizes
By
Dee-Ann Durbin
and
The Associated Press
March 12, 2026
Health
GLP-1s cure hunger for a lot more than food, my study of 600,000 people suggests
By
Ziyad Al-Aly
and
The Conversation
March 6, 2026
Banking
Meat snacks have emerged as the clear winner in America’s seismic GLP-1 consumption shift, while popcorn is down
By
Nick Lichtenberg
February 10, 2026
Commentary
Weight Watchers CEO: what the GLP-1 Super Bowl ads are missing
By
Tara Comonte
February 9, 2026
C-Suite
Pfizer CEO on how he struck a deal with President Trump in 10 days to lower American drug costs
By
Fortune Editors
January 27, 2026
Health
GLP-1s could end up being ‘the first true longevity drug’ as the world battles a rising obesity crisis
By
Angelica Ang
November 21, 2025
C-Suite
Ray Dalio is backing a $1 billion blueberry unicorn that sells berries nearly the size of golf balls
By
Eva Roytburg
November 4, 2025
Health
Adult obesity rate fell from record high—and big pharma is reaping the benefits from mainstream sales of weight-loss drugs like Zepound and Mounjaro
By
Matty Merritt
and
Morning Brew
October 31, 2025
Economy
The ‘quiet alarm bell’ on U.S. health costs: Employers are backed into a corner, and workers are paying the price
By
Ashley Lutz
October 22, 2025
Commentary
Trump wants Medicare to pay for your Ozempic treatment. Taxpayers may foot the bill for billions in fraud
By
Ari Yampolsky
and
Max Voldman
August 12, 2025
Newsletters
Exclusive: The founders of SoulCycle built a startup for relationships, then pivoted to GLP-1 support groups. Now its assets are being acquired by WeightWatchers
By
Emma Hinchliffe
August 7, 2025
Newsletters
Behold, an AI model from OpenAI that’s…open
By
Andrew Nusca
August 6, 2025
Health
Weight-loss drugs should be first step to prevent heart disease, top cardiology group says
By
Michelle Amponsah
and
Bloomberg
June 20, 2025
Lifestyle
Agency warns that weight-loss drugs can decrease effectiveness of birth control pills
By
Beth Greenfield
June 5, 2025
Health
The Ozempic boom could be bad news for restaurants as more than half of GLP-1 users report cutting back on dining out, report finds
By
Sasha Rogelberg
June 4, 2025
Most Popular
Success
Covid gave us hybrid work. The Iran War might give us a four-day week—and this time, experts say it could stick
By
Orianna Rosa Royle
AI
A man let ChatGPT sell his home. It beat every agent's estimate by $100K—and closed in 5 days
By
Jake Angelo
AI
'Godfather of AI' says tech companies aren’t concerned with the AI endgame. They’re focused on short-term profits...
By
Sasha Rogelberg